SLC5A2 and Hypoglycemia: Considering that hypoglycemia is also an important risk factor in DR development, we believe antidiabetic drugs with limited capacity to provoke hypoglycemia (GLP-1RA and SGLT-2 inhibitors) should be used to treat DR patients.